The estimated Net Worth of Harry Jr Penner is at least $1.36 Million dollars as of 6 December 2013. Mr. Penner owns over 17,728 units of Celldex Therapeutics stock worth over $1,296,836 and over the last 15 years he sold CLDX stock worth over $0. In addition, he makes $63,136 as Independent Director at Celldex Therapeutics.
Harry has made over 2 trades of the Celldex Therapeutics stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 17,728 units of CLDX stock worth $144,660 on 6 December 2013.
The largest trade he's ever made was exercising 17,728 units of Celldex Therapeutics stock on 6 December 2013 worth over $144,660. On average, Harry trades about 1,091 units every 62 days since 2009. As of 6 December 2013 he still owns at least 31,144 units of Celldex Therapeutics stock.
You can see the complete history of Mr. Penner stock trades at the bottom of the page.
Dr. Harry H. Penner J.D. serves as Independent Director of the Company. Mr. Penner has served as Chairman and Chief Executive Officer of Nascent BioScience, LLC, a firm engaged in the creation and development of new life science companies since 2001. From 1993 to 2001, Mr. Penner was President, Chief Executive Officer and Vice Chairman of Neurogen Corporation. From 1985 to 1993, Mr. Penner was an Executive Vice President of Novo Nordisk A/S, serving from 1988 to 1993 as Executive Vice President for North America and President, Novo Nordisk of North America, and from 1985 to 1988 as the company's Executive Vice President and General Counsel in Denmark. He has served as BioScience Advisor to the Governor and the State of Connecticut, as Co-Chairman of BioCT (formerly Connecticut United for Research Excellence), and as Chairman of the Connecticut Board of Governors of Higher Education and the Connecticut Technology Council. Mr. Penner is currently Chairman of the Board of CaroGen Corporation. Mr. Penner is also Chairman of the Board of Affinimark Technologies, Inc., NeuroCyte Therapeutics, Inc. and QCDx LLC, and a board member of OmaxHealth, Inc., all of which he is a founder. Mr. Penner received a B.A. from the University of Virginia, a J.D. from Fordham University, and an L.L.M. in International Law from New York University.
As the Independent Director of Celldex Therapeutics, the total compensation of Harry Penner at Celldex Therapeutics is $63,136. There are 16 executives at Celldex Therapeutics getting paid more, with Ronald Pepin having the highest compensation of $1,225,030.
Harry Penner is 74, he's been the Independent Director of Celldex Therapeutics since 2008. There are 2 older and 22 younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics Inc. is Herbert Conrad, 87, who is the Independent Director.
Harry's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827.
Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil und Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
Celldex Therapeutics executives and other stock owners filed with the SEC include: